Skip to main content
. 2001 Jun 15;7(3):411–414. doi: 10.3748/wjg.v7.i3.411

Table 1.

Responses to treatment at the end of therapy n (%)

T-a1 (n = 18)
IFN-α (n = 33)
HC (n = 30)
(after 6 mo of follow-up)
ALT normalization 7 (38.9) 16 (48.5) 5 (16.7)
HBV DNA-negative 10 (55.6)b 22 (66.7)b 2 (6.7)
ALT normal/HBV DNA and HBeAg-negative 6 (33.3) 15 (45.5)b 1 (3.3)
b

P < 0.01, vs HC.